Cyp Substrates has 4 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aldesleukin, Talquetamab, Epcoritamab-Bysp. Patients taking Cyp Substrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Major
- 2
- Moderate
- 2
Major (2)
- Cyp Substrates + Aldesleukin— Aldesleukin causes release of cytokines that may suppress CYP enzyme activity, resulting in increased exposure of CYP su…
- Cyp Substrates + Talquetamab— Talquetamab causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substr…
Moderate (2)
- Cyp Substrates + Epcoritamab-Bysp— Epcoritamab-bysp causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP s…
- Cyp Substrates + Linvoseltamab-Gcpt— Linvoseltamab-gcpt causes cytokine release that may suppress CYP enzyme activity, increasing CYP substrate exposure and …